IL33 and colorectal carcinoma: The same study also assessed the role of IL-33 and eosinophils in a heterotypic subcutaneous model of CRC, and found that the anti-tumoral effect of IL-33 was abrogated in mice genetically deficient in eosinophils (ΔdblGATA-1), and adoptive transfer of eosinophils restored the anti-tumour efficacy of IL-33 treatment.